BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response

Tai Sung Lee, Wanlong Ma, Xi Zhang, Maher Albitar, Francis Giles, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalLetter

Original languageEnglish (US)
Number of pages1
JournalMolecular cancer therapeutics
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2010
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response. / Lee, Tai Sung; Ma, Wanlong; Zhang, Xi; Albitar, Maher; Giles, Francis; Cortes, Jorge; Kantarjian, Hagop.

In: Molecular cancer therapeutics, Vol. 9, No. 3, 01.03.2010.

Research output: Contribution to journalLetter

Lee, Tai Sung ; Ma, Wanlong ; Zhang, Xi ; Albitar, Maher ; Giles, Francis ; Cortes, Jorge ; Kantarjian, Hagop. / BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response. In: Molecular cancer therapeutics. 2010 ; Vol. 9, No. 3.
@article{c63c2bb0bb434cd1900e7e0daa3a2561,
title = "BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response",
author = "Lee, {Tai Sung} and Wanlong Ma and Xi Zhang and Maher Albitar and Francis Giles and Jorge Cortes and Hagop Kantarjian",
year = "2010",
month = "3",
day = "1",
doi = "10.1158/1535-7163.MCT-09-1116",
language = "English (US)",
volume = "9",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - BCR-ABL1INS35 is not uncommon in CML patients and is related to resistance and sensitivity to inhibitors in CML treatment - Response

AU - Lee, Tai Sung

AU - Ma, Wanlong

AU - Zhang, Xi

AU - Albitar, Maher

AU - Giles, Francis

AU - Cortes, Jorge

AU - Kantarjian, Hagop

PY - 2010/3/1

Y1 - 2010/3/1

UR - http://www.scopus.com/inward/record.url?scp=77949765312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949765312&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-09-1116

DO - 10.1158/1535-7163.MCT-09-1116

M3 - Letter

AN - SCOPUS:77949765312

VL - 9

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -